Program
BEBT-109
A development code. Also written as “BEBT-109 Capsules” and “BEBT-109 Capsule”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by BeBetter Med.
Furthest: phase 2, since Jul 17, 20242 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeBetter Med | 22 open or running | phase 2since Jul 17, 2024 | Jul 17, 2024 | Jun 2027phase 2 · NCT06514027 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 17, 2024First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06514027 · 30 planned · China
- Nov 25, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06706713 · 200 planned · China
Ahead
- Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06514027
TargetBeta
EGFR →read by rule
“Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC With EGFR Exon 20 Insertion Mutations: a Phase 1B, Dose Escalation and Expansion Trial”study text, by rule · the study
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06706713Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Dec 31, 2025 | 200 |
| NCT06514027Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jun 2027 | 30 |
How it is read
Names in the registry
- “BEBT-109 Capsules”, 1 entry
- “BEBT-109 Capsule”, 1 entry
Codes read as this program: BEBT109.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.